Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

630

Participants

Timeline

Start Date

June 16, 2017

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions
Smoking Cessation
Interventions
BEHAVIORAL

Questionnaires

Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.

PROCEDURE

Low Dose Computed Tomography Scan

Participants have a CT scan of chest to look for signs of lung cancer.

OTHER

Shared Decision Making + Video

Participants given shared decision making and discussion about screening with the LDCT provider. Participants watch a short video about lung cancer, CT scans, and smoking cessation.

BEHAVIORAL

Cessation Counseling

Brief cessation counseling given by LDCT provider.

BEHAVIORAL

Quitline

Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks.

BEHAVIORAL

Pharmacotherapy Discussion

Participant informed of the risk, benefits and relative efficacy of cessation medications and to assess their medication preferences, expectations and medical suitability for either option. At the conclusion of this conversation the patient is provided with an initial supply of the medication jointly decided between provider and patient.

DRUG

Nicotine Patch

Nicotine patch dispensed. Dosing at physician's discretion.

DRUG

Anti-Smoking Drug

Varenicline or Buproprion prescribed by study doctor with directions of when and how much of anti-smoking drug that should be taken each time.

BEHAVIORAL

Tobacco Treatment Program

Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,

OTHER

Carbon Monoxide (CO) Level Test

Participant asked to blow air through a CO-measuring device.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Pfizer

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER